ABBOTT LABORATORIES Cash and Restricted Cash
ABBOTT LABORATORIES (ABT) had Cash and Restricted Cash of $6.80 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-04-29
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.80B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.52B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.51B.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.95B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-03-31 | $6.80B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $8.52B 10-Q · filed 2026-04-29 |
| 2025-09-30 | $7.51B 10-Q · filed 2025-10-29 |
| 2025-06-30 | $6.95B 10-Q · filed 2025-07-30 |
| 2025-03-31 | $6.53B 10-Q · filed 2026-04-29 |
| 2024-12-31 | $7.62B 10-Q · filed 2026-04-29 |
| 2024-09-30 | $7.56B 10-Q · filed 2025-10-29 |
| 2024-06-30 | $6.99B 10-Q · filed 2025-07-30 |
| 2024-03-31 | $6.28B 10-Q · filed 2025-04-30 |
| 2023-12-31 | $6.90B 10-K · filed 2026-02-20 |
| 2023-09-30 | $6.71B 10-Q · filed 2024-10-31 |
| 2023-06-30 | $7.83B 10-Q · filed 2024-07-31 |
| 2023-03-31 | $9.16B 10-Q · filed 2024-05-02 |
| 2022-12-31 | $9.88B 10-K · filed 2026-02-20 |
| 2022-09-30 | $9.59B 10-Q · filed 2023-11-01 |
| 2022-06-30 | $8.94B 10-Q · filed 2023-08-03 |
| 2022-03-31 | $7.67B 10-Q · filed 2023-05-04 |
| 2021-12-31 | $9.80B 10-K · filed 2025-02-21 |
| 2021-09-30 | $9.30B 10-Q · filed 2022-11-01 |
| 2021-06-30 | $8.66B 10-Q · filed 2022-08-02 |
| 2021-03-31 | $8.05B 10-Q · filed 2022-05-03 |
| 2020-12-31 | $6.84B 10-K · filed 2024-02-16 |
| 2020-09-30 | $4.48B 10-Q · filed 2021-11-03 |
| 2020-06-30 | $4.76B 10-Q · filed 2021-08-04 |
| 2020-03-31 | $3.38B 10-Q · filed 2021-05-05 |
| 2019-12-31 | $3.86B 10-K · filed 2023-02-17 |
| 2019-09-30 | $4.09B 10-Q · filed 2020-11-04 |
| 2019-06-30 | $3.14B 10-Q · filed 2020-07-29 |
| 2019-03-31 | $3.02B 10-Q · filed 2020-04-29 |
| 2018-12-31 | $3.84B 10-K · filed 2022-02-18 |
| 2018-09-30 | $7.37B 10-Q · filed 2019-10-31 |
| 2018-06-30 | $3.06B 10-Q · filed 2019-07-31 |
| 2018-03-31 | $3.86B 10-Q · filed 2019-05-01 |
| 2017-12-31 | $9.41B 10-K · filed 2021-02-19 |
| 2017-09-30 | $11.01B 10-Q · filed 2018-10-31 |
| 2017-06-30 | $9.68B 10-Q · filed 2018-08-01 |
| 2017-03-31 | $8.71B 10-Q · filed 2018-05-02 |
| 2016-12-31 | $18.62B 10-K · filed 2020-02-21 |
| 2015-12-31 | $5.00B 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |